Nacresertib clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2025
How each study uses nacresertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Nacresertib
- 3
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses nacresertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult ParticipantsCompletedPhase 1AbbVieNCT07649954Written as Nacresertib
- A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese ParticipantsCompletedPhase 1AbbVieNCT07600762Written as Nacresertib
- A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult ParticipantsCompletedPhase 1AbbVieNCT07566130Written as nacresertib
Codes
What other systems call nacresertib · ClinicalTrials.gg INT017282
- UNII (FDA) MB3QBD4BE7NACRESERTIBOne source FDA
- NCI Thesaurus C213407NacresertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | MB3QBD4BE7 | NACRESERTIB | One source FDA |
| NCI Thesaurus | C213407 | Nacresertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.